Get the Stockscreener App
0.685
2.22%
0.0149
After Hours:
.72
0.035
+5.11%
Shuttle Pharmaceuticals Holdings Inc stock is traded at $0.685, with a volume of 11,874.
It is up +2.22% in the last 24 hours and down -23.03% over the past month.
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
See More
Previous Close:
$0.6701
Open:
$0.7
24h Volume:
11,874
Relative Volume:
0.11
Market Cap:
$2.79M
Revenue:
-
Net Income/Loss:
$-7.35M
P/E Ratio:
-1.4891
EPS:
-0.46
Net Cash Flow:
$-5.48M
1W Performance:
-12.78%
1M Performance:
-23.03%
6M Performance:
+102.66%
1Y Performance:
+75.64%
1-Day Range:
$0.685
$0.7299
1-Week Range:
$0.6319
$0.798
52-Week Range:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Name
Shuttle Pharmaceuticals Holdings Inc
Sector
Phone
(240) 403-4212
Address
401 PROFESSIONAL DRIVE, GAITHERSBURG
Compare SHPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.685 | 2.79M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Latest News
Shuttle Pharmaceuticals expands glioblastoma trial - MSN
Form 424B3 Shuttle Pharmaceuticals - StreetInsider.com
BlackRock MuniHoldings New York Quality Fund Enters Standstill Agreement with Saba Capital Management - Defense World
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Shuttle Pharma hits 25% mark in glioblastoma trial - MSN
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug - StockTitan
Form S-1 Shuttle Pharmaceuticals - StreetInsider.com
Shuttle Pharmaceuticals (NASDAQ:SHPH) Faces Potential Delisting from Nasdaq due to Minimum Bid Price Requirement Noncompliance - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - The Manila Times
Shuttle Pharmaceuticals CEO to Present Glioblastoma Trial Updates at Lytham Partners Healthcare Summit - StockTitan
Tilray (TLRY) Stock Drops 5.11% Amidst Market Volatility - GuruFocus.com
EZFill Holdings, Inc. Enters Mobile Fueling Vendor Agreement with Amazon - Defense World
Shuttle Pharmaceuticals Holdings, Inc. Engages in Sponsored Research Agreement with UCSF - Defense World
Shuttle Pharma Enters into Sponsored Research Agreement - GlobeNewswire
Shuttle Pharmaceuticals Partners with UCSF for Breakthrough Prostate Cancer Diagnostic Development - StockTitan
Shuttle Pharmaceuticals stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
SHPH stock touches 52-week low at $0.75 amid market challenges - Investing.com UK
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA - GuruFocus.com
Likelihood of Approval and Phase Transition Success Rate ModelRopidoxuridine in Bile Duct Cancer (Cholangiocarcinoma) - GlobalData
Shuttle Pharmaceuticals Initiates Phase 2 Clinical Trial for Glioblastoma Treatment- - Defense World
Shuttle Pharmaceuticals stock hits 52-week low at $0.83 By Investing.com - Investing.com Canada
Shuttle Pharma Expands Patient Enrollment for Phase 2 - GlobeNewswire
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma - TipRanks
Shuttle Pharmaceuticals Launches Phase 2 Trial for Breakthrough Glioblastoma Treatment | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Up - GuruFocus.com
Micro Cap Company Is Soaring On Phase 2 Trial Update - MSN
500: Something went wrong - Investing.com UK
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Shuttle Pharma Provides Third Quarter 2024 Corporate Update - GlobeNewswire
Shuttle Pharma Advances Phase 2 Trial, Secures $4.5M Funding for Cancer Treatment Study | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals’ $4.5 Million Common Stock Offering - Global Legal Chronicle
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News - MSN
Shuttle Pharma Raises $4.5M for Clinical Trials - TipRanks
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
Shuttle Pharmaceuticals Successfully Doses First Patients in Phase 2 Clinical Trial for Glioblastoma Treatment - Defense World
Shuttle Pharma doses three subjects in Phase II glioblastoma treatment trial - Yahoo! Voices
"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs" - Marketscreener.com
SHPHShuttle Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Shuttle Pharmaceuticals dips 6%, prices $3.5M share offering - MSN
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of - GlobeNewswire
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Benzinga
Shuttle Pharma Pays Off Senior Secured Convertible Note - GlobeNewswire
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):